Literature DB >> 20146033

Development of Kaposi's sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient.

Alastair B Law, Gail Ryan, Stephen Lade, H Miles Prince.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20146033     DOI： 10.1007/s12185-010-0497-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  12 in total

1.  Nadir B cell counts are significantly correlated with the risk of Kaposi's sarcoma.

Authors:  Justin Stebbing; Brian Gazzard; Tom Newsom-Davis; Mark Nelson; Steve Patterson; Frances Gotch; Sundhiya Mandalia; Mark Bower
Journal:  Int J Cancer       Date:  2004-01-20       Impact factor: 7.396

2.  Progression of classic Kaposi's sarcoma with rituximab.

Authors:  Keri S Clifford; Marie-France Demierre
Journal:  J Am Acad Dermatol       Date:  2005-07       Impact factor: 11.527

3.  HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma.

Authors:  Paolo Nicoli; Ubaldo Familiari; Marco Bosa; Tiziano Allice; Francesca Mete; Alessandro Morotti; Daniela Cilloni; Giuseppe Saglio; Angelo Guerrasio
Journal:  Int J Hematol       Date:  2009-09-12       Impact factor: 2.490

Review 4.  [Two HHV8-related illnesses in a HIV-negative patient: Kaposi's sarcoma and multicentric Castleman's disease. Response to treatment with Rituximab and CHOP].

Authors:  M A Pastor; B Vasco; J M Mosquera; G Debén; P Bautista; L Requena
Journal:  Actas Dermosifiliogr       Date:  2006 Jul-Aug

5.  Rituximab therapy for HIV-associated Castleman disease.

Authors:  Anne-Geneviève Marcelin; Laurent Aaron; Christine Mateus; Emmanuel Gyan; Isabelle Gorin; Jean-Paul Viard; Vincent Calvez; Nicolas Dupin
Journal:  Blood       Date:  2003-07-03       Impact factor: 22.113

6.  Lymph nodes involved by multicentric Castleman disease among HIV-positive individuals are often involved by Kaposi sarcoma.

Authors:  Kikkeri N Naresh; Alexandra J Rice; Mark Bower
Journal:  Am J Surg Pathol       Date:  2008-07       Impact factor: 6.394

Review 7.  Castleman disease.

Authors:  Anu Dham; Bruce A Peterson
Journal:  Curr Opin Hematol       Date:  2007-07       Impact factor: 3.284

8.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.

Authors:  J Soulier; L Grollet; E Oksenhendler; P Cacoub; D Cazals-Hatem; P Babinet; M F d'Agay; J P Clauvel; M Raphael; L Degos
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113

9.  Brief communication: rituximab in HIV-associated multicentric Castleman disease.

Authors:  Mark Bower; Tom Powles; Sarah Williams; Tom Newsom Davis; Mark Atkins; Silvia Montoto; Chloe Orkin; Andy Webb; Martin Fisher; Mark Nelson; Brian Gazzard; Justin Stebbing; Peter Kelleher
Journal:  Ann Intern Med       Date:  2007-12-18       Impact factor: 25.391

10.  Multicentric Castleman's disease and Kaposi's sarcoma in a cyclosporin treated, HIV-1 negative patient: case report.

Authors:  JM Bollen; AM Polstra; AC Van Der Kuyl; JF Weel; LA Noorduyn; MHJ Van Oers; M Cornelissen
Journal:  BMC Blood Disord       Date:  2003-12-11
View more
  7 in total

1.  Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein.

Authors:  Deboeeta Chatterjee; Bala Chandran; Edward A Berger
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

2.  Kaposi's Sarcoma After Autologous Stem-Cell Transplantation and Rituximab Treatment.

Authors:  Shamir Geller; Mark A Dickson; Klaus J Busam; Patricia L Myskowski
Journal:  J Oncol Pract       Date:  2018-07-25       Impact factor: 3.840

3.  Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease: a report of three cases.

Authors:  Xinping Zhou; Juying Wei; Yinjun Lou; Gaixiang Xu; Min Yang; Hui Liu; Liping Mao; Hongyan Tong; Jie Jin
Journal:  Front Med       Date:  2017-04-03       Impact factor: 4.592

Review 4.  Multicentric Castleman's disease: a challenging diagnosis.

Authors:  Györgyi Műzes; Ferenc Sipos; Judit Csomor; Lídia Sréter
Journal:  Pathol Oncol Res       Date:  2013-03-21       Impact factor: 3.201

5.  An immunotoxin targeting the gH glycoprotein of KSHV for selective killing of cells in the lytic phase of infection.

Authors:  Yingyun Cai; Edward A Berger
Journal:  Antiviral Res       Date:  2011-03-31       Impact factor: 10.103

6.  Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients.

Authors:  Xuanye Zhang; Huilan Rao; Xiaolu Xu; Zhihua Li; Bing Liao; Hongmei Wu; Mei Li; Xiuzhen Tong; Juan Li; Qingqing Cai
Journal:  Cancer Sci       Date:  2017-12-28       Impact factor: 6.716

7.  Tocilizumab monotherapy in a patient with rheumatoid arthritis and iatrogenic Kaposi sarcoma.

Authors:  Francesca Ingegnoli; Athanasia Tourlaki; Roberta Gualtierotti
Journal:  Clin Drug Investig       Date:  2014-02       Impact factor: 3.580
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.